Downloads
White Paper: 8 Questions To Ask Before Planning Your Single-Use Biomanufacturing Facility
Deployment of new GMP biomanufacturing capacity is a battle of tradeoffs. Push to accelerate your timetable? Cost or quality considerations must be compromised. Need to drive down total investment? Build-out time or quality must be sacrificed. As single-use technology establishes wider acceptance, certain tradeoffs may be lessened, but serious challenges remain.
Overcoming the limitations intrinsic to conventional biomanufacturing strategies requires a fundamental rethinking of bioproduction architecture. With its FlexFactory® biomanufacturing platform and a deeply experienced team to support its effective implementation, Xcellerex offers a new level of freedom from historical limitations.
In this paper, we examine eight critical considerations facing the biopharmaceutical and vaccine production landscape, and how each is addressed with this new, proven approach to biomanufacturing.
The content you requested is only available to registered users of Bioresearch Online. By registering now, you'll get access to this piece of content and thousands of additional articles and product reviews across our entire network of sites.
